Trial intelligence / Profile preview

Zanidatamab plus chemotherapy with or without tislelizumab in HER2-positive unresectable or metastatic gastroesophageal adenocarcinoma

2023-510319-20-00Phase 3Authorised

Sponsor: Jazz Pharmaceuticals plc
Start: Oct 2024
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 32

Overview

Phase 3, randomised trial of zanidatamab in gastroesophageal junction adenocarcinoma (3 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoints: Progression-free survival by BICR (RECIST 1.1) and Overall survival. Planned start Oct 2024; status: authorised.

Drugs

zanidatamab

Conditions

gastroesophageal junction adenocarcinoma

Beyond the preview

Go deeper on 2023-510319-20-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2023-510319-20-00.